English
ThisiscontentfromClinicalKey
Sign up for your free ClinicalKey trial today! Your first step in getting the right answers when you need them. ClinicalKey is a clinical knowledge solution designed to help healthcare professionals and students find the right answers by providing in-depth, evidence-based knowledge – all from one resource.
Most patients with mpox have mild, self-limited disease, which can be managed with supportive care alone r18
Consider systemic antiviral treatment for the following patients after consultation with state health authorities or CDC through the Emergency Operations Center (telephone, 1-770-488-7100): r18
Currently there are no treatments approved specifically for mpox virus infection, but several antiviral agents originally developed for treatment of smallpox and other viral infections may be considered; they may be obtained from the Strategic National Stockpile upon request from state health authorities after consultation with CDC. Efficacy data for these agents are lacking, owing to infeasibility of human smallpox experimentation r18
Other management considerations should be individualized depending on specific mpox disease manifestations or disease-related complications, and may include the following: r69r70
Additional guidance has been developed for the following specific clinical manifestations of mpox: